findmyKOL
Clinical trialNCT00161213CompletedPhase 2Interventional

Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic Cancer

SponsorUniversity of Medicine and Dentistry of New JerseyEnrollment44Pancreatic Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with imatinib mesylate may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with imatinib mesylate works as first-line therapy in treating patients with locally advanced or metastatic pancreatic cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University

    Chicago, Illinois, United States

  • Centrastate Medical Center

    Freehold, New Jersey, United States

  • Cancer Institute of New Jersey at Hamilton

    Hamilton, New Jersey, United States

  • Jersey Shore Cancer Center at Jersey Shore University Medical Center

    Neptune City, New Jersey, United States

  • Cancer Institute of New Jersey at Umdnj - Robert Wood Johnson Medical School

    New Brunswick, New Jersey, United States

  • Central Jersey Oncology Group

    New Brunswick, New Jersey, United States

  • Saint Peter'S University Hospital

    New Brunswick, New Jersey, United States

  • New Jersey Medical School

    Newark, New Jersey, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gemcitabine →Imatinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 2005
Primary completion
31 Oct 2010
Completion
31 Oct 2010
Last update posted
14 Aug 2023
Registered enrollment
44
Registry id
NCT00161213
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.